Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.49 |
| ▸ | CA2 | P00918 | 6/20 | 0.49 |
| ▸ | CA7 | P43166 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487502 | 0.86 | KMT2A (0.58) | HTR2AHTR2CHTR2BSMN1; SMN2MEN1 | |
| SCHEMBL20946394 | 0.83 | KMT2A (0.55) | SMN1; SMN2MEN1CYP2C19KMT2ACA1 | |
| SCHEMBL21396291 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2MEN1CYP2C19KMT2AHTT | |
| SCHEMBL13007739 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1CYP2C19KMT2AHTT | |
| SCHEMBL12298707 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1CYP2C19KMT2AHTT | |
| SCHEMBL24120598 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1CYP2C19KMT2ACA1 | |
| SCHEMBL10233020 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1CYP2C19KMT2ACA1 | |
| SCHEMBL26098146 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1CYP2C19KMT2ACA1 | |
| SCHEMBL17878013 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1CYP2C19KMT2AHTT | |
| SCHEMBL10233022 | 0.79 | ALDH1A1 (0.51) | SMN1; SMN2MEN1CYP2C19KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174299-B | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligand and methods of use | 百济神州有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20220281876-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2022-09-08 | — | — | US | disclosed |
| CN-114174299-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281876-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | HTR2A 4516/4885HTR2C 4101/4885HTR2B 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.